PMLiVE The EMA's Committee for Medicinal Products for Human Use (CHMP) backed the drug for use in the treatment of lung cancer in a list of opinions that also saw recommendations for medicines from Novartis, Takeda and Gilead. The endorsement for Giotrif ... and more »
Clinical Endocrinology News Digital Network ... single-agent drug therapy for type 2 diabetes between 1999 and 2001 showed that 5 years after starting therapy, patients who started on metformin had a 23% lower 5-year risk for dementia compared with patients who started on a thiazolidinedione ...
Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Pharmaceutical Business Review Combination of alogliptin with metformin HCl, KAZANO, is an anti-diabetes medication formulated in a single tablet in addition to single tablet regeime OSENI that combines alogliptin with the thiazolidinedione (TZD) pioglitazone. Share: Delicious; Digg ...
4-traders (press release) The active comparators in the studies were insulin, a sulphonylurea (SU), a thiazolidinedione (TZD), and a dipeptidyl peptidase four inhibitor (DPP-4). Albiglutide is not approved for use anywhere in the world. ... Harmony 2 (Abstract number: 2013-LB ... and more »
Guardian Express Some clinical studies have shown that thiazolidinedione drugs can potentially increase the risk of having diabetic macular edema (a swelling in the eye that impairs vision) in patients with type 2 diabetes. Here are some of the alternative supplements ... and more »
Healio The HR for rosiglitazone vs. metformin/ sulfonylurea for the endpoint of CV death/MI/stroke was 0.95 (95% CI, 0.78-1.17) vs. 0.93 (95% CI, 0.74-1.15) for the original RECORD results. Treatment comparisons for MI (HR=1.13; 95% CI, 0.8-1.59) and mortality ...
